Bone Marrow Failure Syndromes
Optimizing Outcomes
Worldwide through
Disease Understanding
 |
||
|
How to Obtain AMA PRACategory 1 Credit(s)™
|
|
 |
||
Release Date: February 28, 2009
Expiration Date: February 28, 2011
Estimated Time of Completion: 3 hours
Description
Bone Marrow Failure Syndromes: Optimizing Outcomes Worldwide through Disease Understanding Podcast Series was recorded in front of a live audience during a satellite symposium at the ASH Annual Meeting. The goal of this series is to review the pathobiology of these disorders, describe the variations in disease patterns across global regions, and evaluate the rationale for therapies and their evidence-based, clinically relevant application.
Objectives
At the conclusion of these activities, the participant will be able to do the following:
Changing Face of Bone Worldwide: Epidemiology and Treatment Overview
- Describe the risk factors for developing aplastic anemia.
- Describe the epidemiology of myelodysplastic syndromes.
Epigenetic Advances: Correlating Response to Modification of the Clone
- Review the possible mechanisms of action of epigenetic therapy in bone marrow failure disorders including myelodysplasia.
- Discuss the results of recent studies which address the question of whether response to epigenetic therapy results from loss of the malignant clone or reversal of epigenetic abnormalities.
Preventing AML Transformation
- Review of treatments having demonstrated that they could have an impact on natural history of MDS and its progression (especially to AML).
Rationally Targeting the Molecular Underpinnings of the Disease
- Discuss the pathophysiology of PNH and its therapy.
- Review the efficacy and safety of lenalidomide in del(5q) MDS.
Diagnostic Advances: Beyond the Karyotype
- Explain the role of cytogenetics in the diagnosis of MDS and limitations of this technology with regard to diagnostic yield.
- Identify techniques to detect and the diagnostic implications of novel recurrent clonal lesions in MDS.
Bringing Clinical Trials to Patients
- Discuss some of the obstacles to performing clinical trials in a community setting.
- Review a new model for clinical trial delivery in a community setting.
- Demonstrate how a Patient Contact Registry can be an effective means of recruiting patients for clinical trials.
- And explain how patient educators can instruct patients how to find clinical trials and how to contact Trial Coordinators.
Target Audience
This educational activity is designed for medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied healthcare professionals treating patients with hematologic malignancies. In addition, members of patient advocacy groups will benefit from this program.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
| Mikkael Sekeres, MD, MS Associate Professor of Medicine Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio |
Presenting Faculty
| Louis DeGennaro, PhD Chief Scientific Officer Leukemia and Lymphoma Society White Plains, New York |
James G. Herman, MD Associate Professor The Johns Hopkins University School of Medicine Baltimore, Maryland |
| Pierre Fenaux, MD, PhD Professor of Hematology Avicenne Hospital/University of Paris Bobigny, France |
Alice Houk, MS Director, Health Professional Programs Aplastic Anemia & Myelodysplastic Syndromes International Foundation, Inc Churchton, Maryland |
| Aristoteles A.N. Giagounidis, MD, PhD Associate Professor of Medicine St. Johannes Hospital Duisburg, Germany |
Jaroslaw P. Maciejewski, MD, PhD Chief, Hematopoieses & Experimental Hematology Section Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Pierre Fenaux, MD, PhD | |||
| Membership on advisory committee/review panels: |
Amgen; Celgene Corporation; Cephalon; Janssen-Cilag; Novartis; Pharmion Corporation; Roche | ||
| Aristoteles A.N. Giagounidis, MD, PhD | |||
| Consulting: | Celgene Corporation; Novartis; Ortho Biotech; Pharmion Corporation | ||
| Teaching and Speaking: | Novartis; Pharmion Corporation; Roche | ||
| Stock Owner: | Pfizer, Inc. | ||
| James G. Herman, MD | |||
| Consulting: | OncoMethylome Sciences; Pharmion Corporation | ||
| Intellectual Property Rights: | OncoMethylome Sciences | ||
| Jaroslaw P. Maciejewski, MD, PhD | |||
| Membership on advisory committee/review panels: |
Celgene Corporation
|
||
| Mikkael Sekeres, MD, MS | |||
| Consulting: | Pharmion Corporation | ||
| Teaching and Speaking: | Celgene Corporation | ||
| Research: | Celgene Corporation | ||
The following faculty has indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:
Louis DeGennaro, PhD
Alice Houk, MS
The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:
Celgene Corporation
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.
